North America is anticipated to continue its dominance in the worldwide antibody-drug conjugates market during the forecast period, owing to the expansion of key businesses in different business methods such as research and development to increase global market presence. Seattle Genetics and Astellas Pharma, Inc., for example, announced the start date of the first cohort of pivotal phase 2 clinical trials dubbed EV-201 in June 2019. The experimental medicine enfortubmab vedotin, an antibody-drug combination, was discovered to significantly reduce tumor growth in the majority of patients.
Often, biopsies are performed by radiologists, cardiologists, and biologists. The options for biopsy if a cancer is suspected are numerous. The American Cancer Society estimates that 606,880 Americans will die from cancer in 2019 and 1,762,450 new cases will develop. A high incidence of cancer is expected to continue to grow the global market for biopsy devices.
Biologic devices are growing rapidly as the field of medical diagnostics and treatments advances. The United States awarded Medtronic plc with a $6.5 billion contract. Biopsy procedures, stereo electroencephalography (EEG) electrode placement, and placement of bone anchors for catheter placements have all been approved by the FDA for the Stealth Autoguide system.
Because of the high prevalence of cancer in the region, the number of people opting for biopsies in Asia Pacific has steadily increased. The incidence rate of thyroid cancer in India increased from 2.4 to 3.9 in women and from 0.9 to 1.3 in men between 2004/05 and 2013/14, a relative increase of 62 percent and 48 percent, respectively, according to the study, 'Trends in thyroid cancer incidence in India,' published in May 2018 in the Journal of Clinical Oncology. As a result, the market for biopsy tools is expected to grow considerably throughout the forecast period.
The variety of biopsy devices available depends on their functionality and application. In addition to simple and easy-to-use gadgets, there are those designed to make life more convenient, and others that are more high-end or designed to endure heavy use. There are gadgets that can process everything automatically. Hamilton Company, for example, worked with Enable Biosciences in June 2019 to ensure fully automated processing of up to 96 liquid biopsy samples at once using a revolutionary ultrasensitive and highly specific immunoassay in a hands-free workflow.
The global biopsy instruments market is anticipated to hit a new high in the next five years. Because of the growing senior population in countries such as the United States and the United Kingdom, it is becoming increasingly important for healthcare practitioners to have the right tools to evaluate and diagnose diseases, infections, abnormalities, and cancers in these populations.